Fisher Asset Management LLC Reduces Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Fisher Asset Management LLC reduced its holdings in Novo Nordisk A/S (NYSE:NVO) by 3.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 14,193,693 shares of the company’s stock after selling 554,390 shares during the period. Fisher Asset Management LLC owned about 0.32% of Novo Nordisk A/S worth $1,468,338,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in NVO. Jennison Associates LLC boosted its holdings in shares of Novo Nordisk A/S by 100.3% in the 3rd quarter. Jennison Associates LLC now owns 23,419,405 shares of the company’s stock valued at $2,129,761,000 after acquiring an additional 11,727,507 shares during the last quarter. Polen Capital Management LLC purchased a new stake in Novo Nordisk A/S during the third quarter worth $718,995,000. FMR LLC boosted its holdings in Novo Nordisk A/S by 122.7% during the third quarter. FMR LLC now owns 12,077,501 shares of the company’s stock worth $1,098,328,000 after buying an additional 6,654,614 shares in the last quarter. Morgan Stanley boosted its holdings in Novo Nordisk A/S by 96.5% during the third quarter. Morgan Stanley now owns 9,215,098 shares of the company’s stock worth $838,021,000 after buying an additional 4,526,199 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its holdings in Novo Nordisk A/S by 91.7% during the third quarter. Loomis Sayles & Co. L P now owns 9,097,808 shares of the company’s stock worth $827,354,000 after buying an additional 4,350,862 shares in the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Trading Down 3.1 %

NVO stock traded down $3.97 during mid-day trading on Thursday, hitting $125.24. 4,725,325 shares of the company were exchanged, compared to its average volume of 4,803,304. The company has a quick ratio of 0.64, a current ratio of 0.82 and a debt-to-equity ratio of 0.19. The firm has a market capitalization of $562.02 billion, a P/E ratio of 46.34, a PEG ratio of 2.14 and a beta of 0.43. The business has a fifty day simple moving average of $127.22 and a 200-day simple moving average of $112.70. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $138.28.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.71 EPS for the quarter, beating the consensus estimate of $0.66 by $0.05. Novo Nordisk A/S had a net margin of 36.03% and a return on equity of 90.36%. The business had revenue of $9.51 billion during the quarter, compared to analyst estimates of $9.14 billion. On average, equities research analysts predict that Novo Nordisk A/S will post 3.32 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have issued reports on NVO. UBS Group started coverage on shares of Novo Nordisk A/S in a report on Tuesday, January 16th. They set a “neutral” rating on the stock. Morgan Stanley started coverage on shares of Novo Nordisk A/S in a research report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 target price for the company. BMO Capital Markets started coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 target price for the company. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Thursday, April 18th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, Novo Nordisk A/S currently has an average rating of “Moderate Buy” and an average price target of $133.60.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.